<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Escudero DJ</submitter><funding>US National Institutes of Health (NIH)</funding><funding>NICHD NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>NIMH NIH HHS</funding><funding>Brown University Richard B</funding><pagination>18899</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3969508</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17</volume><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Studies examining the use of pre-exposure prophylaxis (PrEP) to prevent HIV transmission among people who inject drugs (PWIDs) have not been adequately summarized. Recently, the Bangkok Tenofovir Study has shown that PrEP may be effective at reducing new HIV infections among this high-risk group. This randomized controlled trial was the first study to specifically examine the efficacy of PrEP among PWIDs. In this review, we present the current state of evidence regarding the use of PrEP to prevent HIV infection in PWID populations, and set an agenda for future research to inform the most effective implementation of PrEP in the context of existing evidence-based HIV prevention strategies.&lt;h4>Discussion&lt;/h4>Despite positive trial results confirming that PrEP may prevent </pubmed_abstract><journal>Journal of the International AIDS Society</journal><pubmed_title>HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research.</pubmed_title><pmcid>PMC3969508</pmcid><funding_grant_id>P30 AI042853</funding_grant_id><funding_grant_id>R01-MH083539</funding_grant_id><funding_grant_id>R24 HD041020</funding_grant_id><funding_grant_id>R01 MH106600</funding_grant_id><funding_grant_id>R01 MH083539</funding_grant_id><pubmed_authors>Howe CJ</pubmed_authors><pubmed_authors>Marshall BD</pubmed_authors><pubmed_authors>Escudero DJ</pubmed_authors><pubmed_authors>Lurie MN</pubmed_authors><pubmed_authors>Kerr T</pubmed_authors></additional><is_claimable>false</is_claimable><name>HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research.</name><description>&lt;h4>Introduction&lt;/h4>Studies examining the use of pre-exposure prophylaxis (PrEP) to prevent HIV transmission among people who inject drugs (PWIDs) have not been adequately summarized. Recently, the Bangkok Tenofovir Study has shown that PrEP may be effective at reducing new HIV infections among this high-risk group. This randomized controlled trial was the first study to specifically examine the efficacy of PrEP among PWIDs. In this review, we present the current state of evidence regarding the use of PrEP to prevent HIV infection in PWID populations, and set an agenda for future research to inform the most effective implementation of PrEP in the context of existing evidence-based HIV prevention strategies.&lt;h4>Discussion&lt;/h4>Despite positive trial results confirming that PrEP may prevent </description><dates><release>2014-01-01T00:00:00Z</release><publication>2014</publication><modification>2025-04-22T01:03:08.467Z</modification><creation>2019-03-27T01:24:08Z</creation></dates><accession>S-EPMC3969508</accession><cross_references><pubmed>24679634</pubmed><doi>10.7448/IAS.17.1.18899</doi></cross_references></HashMap>